Astraveus has received a €10.4m ($11m) grant from the French government to develop its cell and gene therapy manufacturing Lakhesys platform.

The grant is part of the French Government’s “Innovation in Biotherapies and Bioproduction” initiative. The non-dilutive funding was granted after a review of the company’s “SKALE” project for increasing performance and digitalisation of Astraveus’ Lakhesys platform by a committee of independent experts.

The current award builds up on Astraveus’ oversubscribed series seed funding, which raised €16.5m ($17.5m) in June. The financiers included AdBio partners, M Ventures, Johnson & Johnson Innovation, and Bpifrance Large Venture.

Lakhesys platform uses single-use microfluidic bioprocessors that mimic organ perfusion, thereby accelerating the molecular exchanges needed to produce therapeutic agents. The Lakhesys platform would allow for more efficient manufacturing and a reduction in labour, floor space and energy requirements, based on a 24 October press release.

As per Astraveus, the Lakhesys platform does not require a large-scale infrastructure, which can potentially reduce costs and processing time for cell and gene therapies.

GlobalData forecasts the cell and gene therapy market to be worth more than $81bn in 2029. This has led to an increase in the number and size of the facilities manufacturing these biologics. In October, Thermo Fisher added single-use bioreactors to its site in St Louis, Missouri, to allow the site to produce cell and gene therapies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

GlobalData is the parent company of Pharmaceutical Technology.

Various governments and charitable foundations have also invested in cell and gene therapy manufacturing with the aim of improving patient access and reducing costs.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by CytivaEditorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.